Health Care Supplies

Tela Bio

Tela Bio released FY2026 Q1 earnings on May 12 After-Market (EST), actual revenue USD 19.06 M (forecast USD 19 M), actual EPS USD -0.2143 (forecast USD -0.19)

Tela Bio to Release FY2026 Q1 Earnings on May 12 After-Market EST, Forecast Revenue USD 19M, EPS USD -0.19

Tela Bio released FY2025 earnings on March 24 After-Market EST, actual revenue USD 80.28 M (forecast USD 80.44 M), actual EPS USD -0.8271 (forecast USD -0.8333)

Tela Bio released FY2025 Q4 earnings on March 24 After-Market EST, actual revenue USD 20.87 M (forecast USD 21.04 M), actual EPS USD -0.1749 (forecast USD -0.18)

Tela Bio to Release FY2025 Q4 Earnings on March 24 After-Market (EST), Forecast Revenue USD 21.04 M, EPS USD -0.18

Tela Bio released FY2025 Q3 earnings on November 13 After-Market (EST), actual revenue USD 20.69M (forecast USD 21.78M), actual EPS USD -0.1899 (forecast USD -0.21)

Tela Bio released FY2025 9 Months Earnings on November 13 After-Market EST, Actual Revenue USD 59.41 M, Actual EPS USD -0.6569

Frank Takkinen Reiterates Buy Rating on TELA Bio

Lake Street Analyst Reiterates Buy Rating on TELA Bio

Tela Bio to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 21.78 M, EPS USD -0.21

Tela Bio released FY2025 Semi-Annual Earnings on August 11 After-Market EST, with actual revenue of USD 38.72 M and EPS of USD -0.4675

Tela Bio released FY2025 Q2 earnings on August 11 After-Market EST, actual revenue USD 20.2 M (forecast USD 20.67 M), actual EPS USD -0.2187 (forecast USD -0.1866)

Tela Bio to release FY2025 Q2 earnings on August 11 After-Market EST, forecast revenue USD 20.67 M, EPS USD -0.1866

Wall Street Zen Downgrades TELA Bio Stock Rating

TELA Bio Launches OviTex Groin Reinforcement Matrix

Tela Bio released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 18.52 M (forecast USD 17.35 M), actual EPS USD -0.2488 (forecast USD -0.2)

TELA Bio Inc Reports Revenue Growth but Higher EPS Loss

TELA Bio Inc Expected to Report a 20-Cent Loss Per Share in Q1 2025

Tela Bio to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 17.35 M, EPS USD -0.2

Tela Bio released FY2024 Annual Earnings on March 20 After-Market (EST), actual revenue 69.3 M USD (forecast 74.72 M USD), actual EPS -1.3265 USD (forecast -1.3366 USD)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TELA

Earnings Watch

Tela Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.06 M

TELA Bio, Inc. (NASDAQ: TELA) announced on May 7, 2026, that its Board of Directors authorized inducement grants of 89,250 restricted stock units to 12 new employees. This allocation, effective May 5, 2026, is in accordance with Nasdaq Rule 5635(c)(4) and is intended to incentivize the new hires as part of their employment packages.

Unusual Whales

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio (NASDAQ: TELA) is set to release its Q1 2026 earnings on May 12, with analysts predicting a loss of $0.14 per share and revenue of $18.6 million. The company previously reported a loss of $0.16 per share for Q1 2025, exceeding estimates. TELA's stock is currently trading at $1.19, with a market cap of $53.24 million. Recent analyst ratings show a mix of buy, hold, and sell recommendations, with an average target price of $2.20. Institutional investors hold 94.35% of TELA's shares, indicating strong interest in the company.

Market Beat

Piper Sandler Cos

Citizens Financial

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

TELA Bio (TELA) Projected to Post Earnings on Tuesday

ESPR

In Friday's pre-market session, Cue Biopharma saw a significant gain of 90.1%, reaching $28.02, while Esperion Therapeutics rose by 57% to $3.14. Other notable gainers included Akanda (+30.26%), Psyence Biomedical (+19.11%), and iSpecimen (+17.2%). Conversely, Akari Therapeutics dropped 25.9% to $4.00, with Senseonics Holdings and Rein Therapeutics also experiencing declines. Summit Therapeutics fell by 20.55% to $17.05, and Sotera Health decreased by 10.75% to $13.89. Q1 earnings reports were released recently for several companies.

benzinga_article

Esperion Therap

Cue BioPharma

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Health Equip

iShares US Healthcare Providers

VG Health

iShares US Pharma

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares US Medical Devices

Akanda

Psyence Biomedical

iSpecimen

Cerus

Akari Therap

Senseonics

Rein Therapeutics

Summit Therapeutics

Sotera Health

Crescent Biopharma

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

12 Health Care Stocks Moving In Friday's Pre-Market Session

TELA Bio shares are trading higher after the company reported preliminary Q1 sales results above prior guidance. Also, the company replaced four board members.

TELA Bio has appointed Joseph Capper as chairman-designate and added Guido Neels, Guy Nohra, and Paul Thomas to its board. Several existing directors will retire after the 2026 Annual Meeting. Capper will assume the chairman role upon election, while the new appointees will fill positions following the resignations of current directors. This restructuring is part of TELA Bio's ongoing governance changes.

TradingView

MiMedx

HeartBeam

Axogen

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

TELA Bio names Joseph Capper chairman; Guido Neels, Guy Nohra, Paul Thomas appointed to board

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | TELA Stock News

StockTitan

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | TELA Stock News

Tela Bio(TELA.US)

Tela Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.06 M

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio (TELA) Projected to Post Earnings on Tuesday

12 Health Care Stocks Moving In Friday's Pre-Market Session

TELA Bio shares are trading higher after the company reported preliminary Q1 sales results above prior guidance. Also, the company replaced four board members.

TELA Bio names Joseph Capper chairman; Guido Neels, Guy Nohra, Paul Thomas appointed to board

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | TELA Stock News